HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#81 / 81 Total
SLNO - Soleno Therapeutics Inc - Stock Price Chart
TickerSLNO [NASD, RUT]
CompanySoleno Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap3.31BEPS (ttm)-4.26
P/E-EPS this Y39.57%
Forward P/E390.05EPS next Y106.99%
PEG-EPS past 5Y20.19%
P/S-EPS next 5Y-
P/B13.45EPS Q/Q-288.57%
Dividend-Sales Q/Q-
Insider Own27.00%Inst Own90.92%
Insider Trans-19.60%Inst Trans14.92%
Short Float14.90%EarningsFeb 27/a
Analyst Recom1.11Target Price99.78
Avg Volume988.55K52W Range36.61 - 73.97
Mar-29-25 10:39PM Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? (Insider Monkey)
Mar-28-25 10:30PM Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? (Insider Monkey) +6.83%
04:25AM Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? (Insider Monkey)
Mar-27-25 04:18PM Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) +37.61%
04:11PM Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger (Bloomberg)
03:40PM Soleno wins FDA approval for Prader-Willi hyperphagia treatment (Pharmaceutical Technology)
02:50PM Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SeekingAlpha)
12:11PM Soleno stock skyrockets on FDA drug approval (Yahoo Finance Video)
08:46AM SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-26-25 05:15PM Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome (GlobeNewswire)
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hirano Patricia CSEE REMARKSApr 01 '25Sale70.113,782265,15627,036Apr 02 05:38 PM
PATRICIA HIRANOOfficerApr 01 '25Proposed Sale70.113,782265,156Apr 01 04:16 PM
Pauls MatthewDirectorMar 28 '25Option Exercise4.605,93727,31012,437Mar 31 07:24 PM
Pauls MatthewDirectorMar 28 '25Sale71.555,937424,7976,500Mar 31 07:24 PM
Yen KristenSEE REMARKSMar 27 '25Option Exercise4.9740,638201,966101,774Mar 31 07:23 PM
123456789
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.